What is 3' bias exactly? I understand it is something caused by the enrichment of poly(A) mRNA using oligo(dT) primer.(or is that wrong?) How does it cause the 3' bias?
-
-
See this previous SeqAnswers thread: http://seqanswers.com/forums/showthread.php?t=9839 -
The thread does not explain what 3' bias is.Comment
-
Since polyA tails are at the 3'-end of mRNA's any method that uses polyA sequence for enrichment is likely to recover fragments from that end.
This leads to a greater chance of having sequences from the 3'-end in the resulting reads as opposed to reads that represent the 5'-end of the molecules.
Originally posted by numfar View PostComment
-
So the mRNA has been fragmented? Is this intentionally?(if so why?)Comment
-
Next generation sequencers, specifically those used for RNA-Seq experiments, require library fragments around 3-400 bases. However, RNA needs to be of good quality (non fragmented) at the beginning for successful mRNA enrichment (or rRNA removal)Originally posted by numfar View Post
Typical RNA-Seq workflow goes a bit like this (based on Illumina TruSeq method):
Enrich mRNA (usually PolyA enrichment by Oligo dT beads x2)
Fragment mRNA to required size (usually metal ion-catalyzed base hydrolysis fragmentation)
Reverse transcribe to make double stranded cDNA
Library prep (end repair, adenylate, ligate adapters, size select, PCR enrich)
QC and Quantify library
SequenceComment
-
Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?
Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating...10-14-2026, 09:55 AM -
Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.
We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing...
Comment